Carnitine palmitoyltransferase 2: Analysis of membrane association and complex structure with a substrate analog

FEBS Letters

Volumn 581, Issue 17, 2007, Pages 3247-3252

  Rufer, Arne C ^a   Lomize, Andrei ^b   Benz, Jörg ^a   Chomienne, Odile ^a   Thoma, Ralf ^a   Hennig, Michael ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Drug discovery; Membrane protein; Type 2 diabetes mellitus

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE 2; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; COMPUTER ANALYSIS; CRYSTAL STRUCTURE; DRUG SCREENING; ENZYME ACTIVITY; ENZYME STABILITY; ENZYME SUBSTRATE COMPLEX; HYDROPHOBICITY; MEMBRANE BINDING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RAT;

ANIMALS; BINDING SITES; CARNITINE; CARNITINE O-PALMITOYLTRANSFERASE; CRYSTALLOGRAPHY, X-RAY; MITOCHONDRIAL MEMBRANES; MODELS, MOLECULAR; MODELS, THEORETICAL; PROTEIN BINDING; PROTEIN DENATURATION; RATS; SUBSTRATE SPECIFICITY;

RATTUS;

EID: 34250808426     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2007.05.080     Document Type: Article

References (35)

1. McGarry J.D., and Brown N.F. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur. J. Biochem. 244 (1997) 1-14
2. Kanamaru T., Shinagawa S., Asai M., Okazaki H., Sugiyama Y., Fujita T., Iwatsuka H., and Yoneda M. Emeriamine, an antidiabetic beta-aminobetaine derived from a novel fungal metabolite. Life Sci. 37 (1985) 217-223
3. Shinagawa S., Kanamaru T., Harada S., Asai M., and Okazaki H. Chemistry and inhibitory activity of long chain fatty acid oxidation of emeriamine and its analogues. J. Med. Chem. 30 (1987) 1458-1463
4. Caspary F., Elliott G., Navé B.T., Verzaal P., Rohrbach M., Das P.K., Nagelkerken L., and Nieland J.D. A new therapeutic approach to treat psoriasis by inhibition of fatty acid oxidation by Etomoxir. Br. J. Dermatol. 153 (2005) 937-944
5. Grynberg A. Effectors of fatty acid oxidation reduction: promising new anti-ischaemic agents. Curr. Pharm. Des. 11 (2005) 489-509
6. Lopaschuk G.D., Wall S.R., Olley P.M., and Davies N.J. Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ. Res. 63 (1988) 1036-1043
7. Lehtihet M., Welsh N., Berggren P.O., Cook G.A., and Sjoholm A. Glibenclamide inhibits islet carnitine palmitoyltransferase 1 activity, leading to PKC-dependent insulin exocytosis. Am. J. Physiol. Endocrinol. Metab. 285 (2003) E438-E446
8. Eaton S., Fukumoto K., Stefanutti G., Spitz L., Zammit V.A., and Pierro A. Myocardial carnitine palmitoyltransferase I as a target for oxidative modification in inflammation and sepsis. Biochem. Soc. Trans. 31 (2003) 1133-1136
9. Mutomba M.C., Yuan H., Konyavko M., Adachi S., Yokoyama C.B., Esser V., McGarry J.D., Babior B.M., and Gottlieb R.A. Regulation of the activity of caspases by l-carnitine and palmitoylcarnitine. FEBS Lett. 478 (2000) 19-25
10. Anderson R.C. Carnitine palmitoyltransferase: a viable target for the treatment of NIDDM?. Curr. Pharm. Des. 4 (1998) 1-16
11. Jenkins D.L., and Griffith O.W. dl-Aminocarnitine and acetyl-dl-aminocarnitine. Potent inhibitors of carnitine acyltransferases and hepatic triglyceride catabolism. J. Biol. Chem. 260 (1985) 14748-14755
12. Jenkins D.L., and Griffith O.W. Antiketogenic and hypoglycemic effects of aminocarnitine and acylaminocarnitines. Proc. Natl. Acad. Sci. USA 83 (1986) 290-294
13. Giannessi F., Chiodi P., Marzi M., Minetti P., Pessotto P., De Angelis F., Tassoni E., Conti R., Giorgi F., Mabilia M., Dell'Uomo N., Muck S., Tinti M.O., Carminati P., and Arduini A. Reversible carnitine palmitoyltransferase inhibitors with broad chemical diversity as potential antidiabetic agents. J. Med. Chem. 44 (2001) 2383-2386
14. Giannessi F., Pessotto P., Tassoni E., Chiodi P., Conti R., De Angelis F., Dell'Uomo N., Catini R., Deias R., Tinti M.O., Carminati P., and Arduini A. Discovery of a long-chain carbamoyl aminocarnitine derivative, a reversible carnitine palmitoyltransferase inhibitor with antiketotic and antidiabetic activity. J. Med. Chem. 46 (2003) 303-309
15. Rufer A.C., Thoma R., Benz J., Stihle M., Gsell B., De Roo E., Banner D.W., Mueller F., Chomienne O., and Hennig M. The crystal structure of carnitine palmitoyltransferase 2 and implications for diabetes treatment. Structure 14 (2006) 713-723
16. Lomize A.L., Pogozheva I.D., Lomize M.A., and Mosberg H.I. Positioning of proteins in membranes: a computational approach. Protein Sci. 15 (2006) 1318-1333
17. Lomize M.A., Lomize A.L., Pogozheva I.D., and Mosberg H.I. OPM: orientations of proteins in membranes database. Bioinformatics 22 (2006) 623-625
18. Hsiao Y.S., Jogl G., Esser V., and Tong L. Crystal structure of rat carnitine palmitoyltransferase II (CPT-II). Biochem. Biophys. Res. Commun. 346 (2006) 974-980
19. Pantoliano M.W., Petrella E.C., Kwasnoski J.D., Lobanov V.S., Myslik J., Graf E., Carver T., Asel E., Springer B.A., Lane P., and Salemme F.R. High-density miniaturized thermal shift assays as a general strategy for drug discovery. J. Biomol. Screen. 6 (2001) 429-440
20. Kabsch W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J. Appl. Cryst. 26 (1992) 795-800
21. McCoy A.J., Grosse-Kunstleve R.W., Storoni L.C., and Read R.J. Likelihood-enhanced fast translation functions. Acta Crystallogr. D Biol. Crystallogr. 61 (2005) 458-464
22. Gerber P.R. Peptidemechanics: a force field for peptides and proteins working with entire residues as small units. Biopolymers 32 (1992) 1003-1017
23. Roversi P., Blanc E., Vonrhein C., Evans G., and Bricogne G. Modelling prior distributions of atoms for macromolecular refinement and completion. Acta Crystallogr., D Biol. Crystallogr. 56 (2000) 1316-1323
24. Murshudov G.N., Vagin A.A., Lebedev A., Wilson K.S., and Dodson E.J. Efficient anisotropic refinement of macromolecular structures using FFT. Acta Crystallogr., D Biol. Crystallogr. 55 (1999) 247-255
25. Brünger A.T. X-PLOR Manual Version 3.1 (1992), Yale University Press, New Haven, CT, USA
26. DeLano W.L. The PyMOL User's Manual (2002), DeLano Scientific, San Carlos
27. Brunecky R., Lee S., Rzepecki P.W., Overduin M., Prestwich G.D., Kutateladze A.G., and Kutateladze T.G. Investigation of the binding geometry of a peripheral membrane protein. Biochemistry 44 (2005) 16064-16071
28. Lomize, A.L., Pogozheva, I.D., Lomize, M.A. and Mosberg, H.I. Key role of hydrophobic interactions for positioning of peripheral proteins in membranes, personal communication.
29. Chothia C. Structural invariants in protein folding. Nature 254 (1975) 304-308
30. Lomize A.L., Pogozheva I.D., and Mosberg H.I. Quantification of helix-helix binding affinities in micelles and lipid bilayers. Protein Sci. 13 (2004) 2600-2612
31. Marsh D. Membrane water-penetration profiles from spin labels. Eur. Biophys. J. 31 (2002) 559-562
32. Fiol C.J., and Bieber L.L. Effects of octylglucoside and triton X-100 on the kinetics and specificity of carnitine palmitoyltransferase. Lipids 23 (1988) 120-125
33. Ramsay R.R., Gandour R.D., and van der Leij F.R. Molecular enzymology of carnitine transfer and transport. Biochim. Biophys. Acta 1546 (2001) 21-43
34. Zimmerberg J., and Kozlov M.M. How proteins produce cellular membrane curvature. Nat. Rev. Mol. Cell. Biol. 7 (2006) 9-19
35. Murthy M.S., and Pande S.V. Mechanism of carnitine acylcarnitine translocase-catalyzed import of acylcarnitines into mitochondria. J. Biol. Chem. 259 (1984) 9082-9089